Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 106.53M P/E - EPS this Y 58.90% Ern Qtrly Grth -
Income -137.29M Forward P/E -0.92 EPS next Y 2.90% 50D Avg Chg -37.00%
Sales - PEG -0.04 EPS past 5Y - 200D Avg Chg -71.00%
Dividend N/A Price/Book 0.40 EPS next 5Y 29.10% 52W High Chg -89.00%
Recommedations 1.90 Quick Ratio 12.52 Shares Outstanding 82.40M 52W Low Chg 25.00%
Insider Own 1.59% ROA -29.30% Shares Float 62.10M Beta 1.69
Inst Own 78.38% ROE -57.91% Shares Shorted/Prior 4.18M/4.57M Price 2.48
Gross Margin - Profit Margin - Avg. Volume 878,087 Target Price 6.40
Oper. Margin - Earnings Date Nov 6 Volume 306,137 Change -1.98%
About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio, Inc. News
11/18/24 Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
11/18/24 Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
11/18/24 Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
11/16/24 Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
11/06/24 Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/05/24 Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
11/01/24 Adicet Bio to Participate in Upcoming Investor Conferences
10/31/24 Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/17/24 Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials
10/16/24 Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
09/30/24 Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
09/30/24 Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
09/19/24 ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
08/27/24 Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/19/24 Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
08/13/24 Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
07/25/24 Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?
07/22/24 Owning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET),
07/08/24 Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
06/24/24 Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
ACET Chatroom

User Image Shiny60 Posted - 1 day ago

$ACET as a person dealing with lupus, this could be a game changer. Don't own any ... yet. Not familiar with these bio companies , feels like throwing darts and hopefully hitting a bullseye.

User Image Cool_Cat Posted - 1 day ago

$ACET Interesting little bio, the only problem is no one knows about it.

User Image NEWBIGTECH Posted - 1 day ago

$ACET

User Image NEWBIGTECH Posted - 1 day ago

$ACET

User Image KING_OF_BIO Posted - 2 days ago

$ACET Our 3 month chart has me a little worried, lucky I'm long here lol

User Image CaughtOnChristmas Posted - 2 days ago

$ACET First patient dosed ADI-001 and Open Enrollment for ADI-270 has begun. IT'S BUY TIME

User Image Gator5326 Posted - 3 days ago

$ACET REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Nov. 18, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

User Image NEWBIGTECH Posted - 3 days ago

$ACET

User Image ra11adw Posted - 3 days ago

$ACET I was so busy with so much discounts in AI and other BIO stocks, I saw this $0.90s didn't buy, big mistake. Next time going to trust instincts, no way this should be under $1 with all the cash it has, forget about catalysts.

User Image KING_OF_BIO Posted - 3 days ago

$ACET Come on...

User Image NEWBIGTECH Posted - 3 days ago

$ACET This is going to be huge.

User Image NEWBIGTECH Posted - 3 days ago

$ACET Currently, the analyst consensus on Adicet Bio is a Strong Buy with an average price target of $6.00. See the top stocks

User Image CaughtOnChristmas Posted - 3 days ago

$ACET 1st patient dosed and the stock in under $1, what are you waiting for?

User Image OpenOutcrier Posted - 3 days ago

$ACET (+5.3% pre) Adicet Bio (ACET) Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - SI https://ooc.bz/l/48442

User Image LewisDaKat Posted - 5 days ago

$ACET News Article Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 https://marketwirenews.com/news-releases/adicet-bio-presents-clinical-biomarker-data-for-off--6545550003051568.html $ACET

User Image FK_Stocks Posted - 6 days ago

$ACET so what am I not seeing here? The ADI-270 phase1/2 trial hasn’t still started recruiting test subjects, the delay of which I would understand pushing shareprice down. But earnins report last week mentioned enrollment would open Q4. Can’t really find any bear theses except for this being a small cap and years away from commercialisation. Should the price drop below one buck, I may sell my shares and rebuy after trend reversal

User Image Bobaloo66 Posted - 6 days ago

$ACET 2x volume on a 7.5% down day? someone knows this is going to fall hard

User Image skyman Posted - 6 days ago

$ACET i think its been falling in sympathy with the other drug stocks because of the Kennedy appointment

User Image Gator5326 Posted - 6 days ago

$ACET Most increased their positions significantly

User Image Gator5326 Posted - 6 days ago

$ACET

User Image Gator5326 Posted - 6 days ago

$ACET RA Capital just added 8.3 M shares. Tang increased share count by 28%

User Image Gator5326 Posted - 6 days ago

$ACET RA Capital was the buyer of those shares! All good in the hood

User Image CaughtOnChristmas Posted - 6 days ago

$ACET now Commodore sold completely out. 3rd tute to sell all shares in last 2 days. Tang disclosed a position on a 13F today but I’m not sure if its a new position. Anyone know?

User Image ishy94 Posted - 1 week ago

$ACET buying here, too cheap not to

User Image OpenHandClosedFist Posted - 1 week ago

$ACET This is getting beat up pretty bad. Are they going out of business or what?

User Image CaughtOnChristmas Posted - 1 week ago

$ACET Cowen Financial sold all 2.7 mil shares, 13F filed today.

User Image FK_Stocks Posted - 1 week ago

$ACET 9600 shares bought for 1.16$. Had to jump in. Good balance sheet, ahead of others and very high tute ownership

User Image Gator5326 Posted - 1 week ago

$ACET Selling makes no sense at all. I’m holding long and strong.

User Image OpenHandClosedFist Posted - 1 week ago

$ACET tax loss selling?

User Image CaughtOnChristmas Posted - 1 week ago

$ACET You might say "why is this down when the market is ripping higher" and my only thought is that retail investors are moving their money into profitable investments.

Analyst Ratings
HC Wainwright & Co. Buy Aug 14, 24
Canaccord Genuity Buy Aug 14, 24
HC Wainwright & Co. Buy Jul 8, 24
HC Wainwright & Co. Buy Jun 24, 24
HC Wainwright & Co. Buy Jun 5, 24
HC Wainwright & Co. Buy May 15, 24
Wedbush Outperform Apr 23, 24
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Mar 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ORBIMED ADVISORS LLC Director Director Jan 25 Buy 2.4 3,125,000 7,500,000 1,255,985 01/26/24
GORDON CARL L Director Director Jan 25 Buy 2.4 3,125,000 7,500,000 1,255,985 01/26/24
Schor Chen President & CEO President & CEO Sep 28 Sell 1.39 11,000 15,290 176,969 10/02/23
Schor Chen President & CEO President & CEO Sep 28 Buy 1.38 11,000 15,180 43,469 10/02/23
GORDON CARL L Director Director Jun 27 Buy 2.09 875,000 1,828,750 748,054 06/29/23
ORBIMED ADVISORS LLC Director Director Jun 27 Buy 2.09 875,000 1,828,750 748,054 06/29/23
Healey Don Chief Technology Off.. Chief Technology Officer Feb 15 Sell 7.5726 4,533 34,327 66,568 02/17/23
Aftab Blake Chief Scientific Off.. Chief Scientific Officer Aug 03 Sell 18.00 6,968 125,424 38,967 08/05/22
Aftab Blake Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 14.50 1,363 19,764 52,903 07/07/22
Galimi Francesco SVP & Chief Medical.. SVP & Chief Medical Officer Apr 01 Option 10.51 15,600 163,956 61,692 04/05/22
Galimi Francesco SVP & Chief Medical.. SVP & Chief Medical Officer Apr 01 Sell 21 15,600 327,600 59,917 04/05/22
Jakobovits Aya Director Director Feb 16 Sell 14.83 4,000 59,320 358,345 02/17/22
Jakobovits Aya Director Director Jan 03 Sell 16.32 24,000 391,680 360,345 02/14/22